Life Sciences

  • July 10, 2026

    Boston Scientific Top Brass Sued Over Pacemaker Recall

    A Boston Scientific Corp. shareholder has filed a derivative lawsuit against the company's current and former directors and top executives, claiming they ignored early signs of an issue with the company's pacemakers that led to a recall and has been connected to four deaths.

  • July 10, 2026

    Ex-Biomedical Worker Axed For Not Altering Data, Suit Says

    A former regulatory affairs specialist for biomedical company Vitara has alleged in New Jersey state court that she was fired in retaliation for refusing to manipulate data in the company's bid to perform the first human trial of its technology aimed at helping premature newborns.

  • July 10, 2026

    4 Firms Advise On $3.4B Apollo, Bayer Contraceptives Deal

    Apollo Global Management has agreed to pay €3 billion ($3.4 billion) for a minority stake in Bayer's long-acting reversible contraceptive business, according to a joint announcement Friday. 

  • July 09, 2026

    NY AG Says 3M, DuPont Hid PFAS Risks For Years

    The New York attorney general on Thursday sued 3M, DuPont and other major chemical manufacturers in state court alleging that for decades they failed to warn the public about the health risks of forever chemicals in consumer goods like cosmetics and food packaging.

  • July 09, 2026

    VSL Reaches $20M Deal Resolving Knockoff Probiotic Claims

    VSL Pharmaceuticals Inc., Sigma-Tau Pharmaceuticals Inc. and Alfasigma USA Inc. have reached a $20 million settlement with customers who allege they bought a knockoff version of a proprietary probiotic formula for gastrointestinal ailments, according to an order preliminarily approving the deal.

  • July 09, 2026

    Judge Skeptical On Restraining Order In Affirming Care Case

    A D.C. federal judge appeared skeptical Thursday that a Federal Trade Commission case against a gender-affirming care organization must be halted while the group wages a separate case against the commission's investigation into the organization.

  • July 09, 2026

    Fed. Circ. Doubts $9M Atty Fees Without Dismissal Attempt

    A Federal Circuit panel didn't seem swayed Thursday that ChromaDex's patent infringement suit against Elysium Health had any merit, but the judges struggled to understand why Elysium never tried to dismiss a case it believed was so weak.

  • July 09, 2026

    Regeneron Cites Medtronic Ruling In Amgen Bundling Case

    Regeneron has told a Delaware federal judge there is new reason to preserve its $407 million win against Amgen over cholesterol drug bundling after a California federal judge found in an analogous case that the plaintiff need not prove the defendant had monopoly power over every item in a bundle.

  • July 09, 2026

    Sandoz's Patent Loss Blocks Antitrust Suit, 4th Circ. Told

    Retired U.S. Circuit Judge Paul R. Michel is backing Amgen against Sandoz's Fourth Circuit appeal, arguing in an amicus brief that the final say over now-nixed allegations of blocked biosimilar competition to arthritis drug Enbrel came when Amgen successfully sued Sandoz for patent infringement.

  • July 09, 2026

    Fed. Circ. Affirms AstraZeneca Win Over $107.5M Verdict

    The Federal Circuit on Thursday upheld a lower court's invalidation of a pair of cancer drug patents that a jury found AstraZeneca infringed, turning back a Pfizer unit's attempt to revive a $107.5 million verdict.

  • July 09, 2026

    Actavis Can't Escape State AG Generic Drug Claims

    A Connecticut federal court has trimmed several claims from state enforcers accusing Actavis of fixing prices for dermatology drug products but allowed most of the claims against the drugmaker to proceed.

  • July 09, 2026

    Sam's Club Reaches Deal With Ex-Worker In Miscarriage Suit

    Sam's Club and a former employee who alleged she suffered a miscarriage after the retailer failed to accommodate work restrictions related to her attempt to become pregnant through in vitro fertilization have reached a settlement.

  • July 08, 2026

    Jazz Patent Suit Over Xyrem Survives Dismissal In NJ

    A New Jersey federal judge has refused to let generic-drug company Tris Pharma Inc. escape a suit claiming its attempt to sell a competing version of Jazz Pharmaceuticals' narcolepsy drug Xyrem infringes a series of patents.

  • July 08, 2026

    AstraZeneca Employee Traded On Icosavax Deal, SEC Says

    The U.S. Securities and Exchange Commission on Wednesday accused a former AstraZeneca Pharmaceuticals LP employee of using nonpublic information to trade ahead of the company's $1.1 billion acquisition of vaccine design company Icosavax Inc., yielding approximately $10,000 in illicit gains.

  • July 08, 2026

    Pa. Superior Court Upholds J&J Win In Talc Cancer Suit

    The Pennsylvania Superior Court on Tuesday upheld a 2025 verdict clearing Johnson & Johnson of liability in a suit alleging that using talc caused a woman's fatal mesothelioma, finding that a lower court didn't err by clarifying the jury's instructions after jurors awarded $22 million in punitive damages.

  • July 08, 2026

    Formula-Maker Sued After Recall And Reports Of Sick Infants

    Infant formula manufacturer Nara Organics Inc. sold milk-based powder that had to be recalled after federal regulators learned that multiple infants who had consumed the product were hospitalized with life-threatening botulism, according to a proposed class action filed Wednesday in New York federal court.

  • July 08, 2026

    PBMs Fight Bid To Add Pharmacy Group To Price-Fixing Suit

    Two pharmacy benefit managers have told a Michigan federal judge that a trade association for small pharmacies should not be allowed to intervene in a price-fixing lawsuit brought by the state's attorney general.

  • July 08, 2026

    Sheppard Adds Transactional, IP Attys In Chicago And San Diego

    Sheppard announced Wednesday that the firm has added an experienced intellectual property attorney focused on life sciences as a San Diego area-based partner, a day after announcing the addition of two Chicago-based transactional partners.

  • July 08, 2026

    Handa, Intas Face Patent Suits Over Exelixis Cancer Drug

    Handa Pharmaceuticals and Intas Pharmaceuticals are wrongly trying to bring to market drugs that would compete with Exelixis Inc.'s blockbuster cancer pill Cabometyx before patents on the medication expire, according to a new lawsuit in Delaware federal court.

  • July 08, 2026

    Biggest Rulings For Patent Attys In 2026: A Midyear Report

    The U.S. Supreme Court clarified the pleading standard for induced infringement of skinny labels, and the Federal Circuit opened the door to increased damages for patent owners. Here's what you need to know about these patent cases and other major decisions from the beginning of 2026.

  • July 07, 2026

    2 Ex-Telehealth Execs Sentenced For $100M Adderall Scheme

    A California federal judge on Tuesday sentenced two former executives of a telehealth company who were convicted of operating a $100 million scheme to illegally distribute Adderall over the internet, fining them $1 million each and giving the founder six years in prison.

  • July 07, 2026

    Illinois Cases To Watch In 2026: Midyear Report

    Mead Johnson is set to go to trial this summer in the first case to make it to a jury in multidistrict litigation claiming baby formula caused a serious gut illness in premature infants, while the U.S. attorney's office in Chicago is facing a possible sanctions hearing over prosecutorial misconduct allegations in two Illinois cases on attorneys' radar for the rest of the year.

  • July 07, 2026

    Regeneron Ducks Amgen's Eylea Antitrust Counterclaims

    A West Virginia federal judge dismissed key counterclaims and defenses Tuesday that Amgen had raised against Regeneron's patent infringement lawsuit targeting bids by multiple would-be rivals to produce biosimilar versions of eye medication Eylea, preserving only arguments that Regeneron waited too long to pursue the patent.

  • July 07, 2026

    CEO Cops To Conspiracy In BigLaw Insider Trading Case

    A Dubai-based CEO and trader has pled guilty in Massachusetts federal court to charges that he worked with a former BigLaw associate and others to carry out a far-reaching insider trading scheme.

  • July 07, 2026

    Align's Invisalign Patents Are Infringed But Invalid, Jury Finds

    A Texas federal jury has found that claims in four patents Invisalign maker Align Technology Inc. asserted against orthodontics company ClearCorrect were invalid, but the jurors also rejected ClearCorrect's antitrust claims against Align.

Expert Analysis

  • Rescheduling Cannabis Marks New Tax Era For Operators

    Author Photo

    As the attorney general takes steps to move cannabis from Schedule I to Schedule III of the Controlled Substances Act, operators and advisers should prepare by considering the significant changes this will bring from tax, state, industry and market perspectives, says Michael Harlow at CohnReznick.

  • Navigating Trade Secret Exceptions In Noncompete Bans

    Author Photo

    Recent and ongoing developments in the noncompete landscape, including a potential decision from the Tenth Circuit in Edwards Lifesciences v. Thompson, could offer tools for employers to bring noncompete agreements within trade secret exceptions amid an era of heightened employee mobility, say attorneys at Sullivan & Cromwell.

  • Series

    Playing Tennis Makes Me A Better Lawyer

    Author Photo

    An instinct to turn pain into purpose meant frequent trips to the tennis court, where learning to move ahead one point at a time was a lesson that also applied to the steep learning curve of patent prosecution law, says Daniel Henry at Marshall Gerstein.

  • Expect Major Shifts In Patent And Trademark Policy This Year

    Author Photo

    New leadership and initiatives promise to bring consequential changes to the U.S. Patent and Trademark Office's practices in 2026, likely favoring patent allowance and issuance, as well as streamlining trademark processes, say attorneys at Knobbe Martens.

  • Class Actions At The Circuit Courts: January Lessons

    Author Photo

    In this month's review of class action appeals, Mitchell Engel at Shook Hardy discusses five rulings from October and November, and identifies practice tips from cases involving consumer fraud, oil and gas leases, toxic torts, and wage and hour issues.

  • Series

    Judges On AI: How Judicial Use Informs Guardrails

    Author Photo

    U.S. Magistrate Judge Maritza Dominguez Braswell at the U.S. District Court for the District of Colorado discusses why having a sense of how generative AI tools behave, where they add value, where they introduce risk and how they are reshaping the practice of law is key for today's judges.

  • What US Cos. Must Know To Comply With Italy's AI Law

    Author Photo

    Italy's newly effective artificial intelligence law means U.S. companies operating in Italy or serving Italian customers must now meet EU AI Act obligations as well as Italy-specific requirements, including immediately enforceable criminal penalties, designated national authorities and sector-specific mandates, say attorneys at Portolano Cavallo.

  • Ag Bill Wording Presents Existential Threat To Hemp Industry

    Author Photo

    A proposal in the agriculture appropriations bill for fiscal year 2026, which excludes almost everything synthesized from cannabis from the legal definition of “hemp,” would have catastrophic consequences for thousands of farmers, medical researchers and businesses by banning everything from intoxicating delta-9 THC products to topical CBD creams, says Alissa "Ali" Jubelirer at Benesch.

  • Series

    Adapting To Private Practice: 5 Tips From Ex-SEC Unit Chief

    Author Photo

    My move to private practice has reaffirmed my belief in the value of adaptability, collaboration and strategic thinking — qualities that are essential not only for successful client outcomes, but also for sustained professional satisfaction, says Dabney O’Riordan at Fried Frank.

  • 5 Drug Pricing Policy Developments To Watch In 2026

    Author Photo

    2026 may prove to be a critical year for drug pricing in the U.S., with potential major shifts including several legislative initiatives moving forward after being in the works for years, and more experimentation on the horizon concerning GLP-1s and Section 340B pricing, say attorneys at Manatt.

  • Patent Applicants Must Get Biologics Enablement Right

    Author Photo

    As artificial intelligence increasingly becomes a core driver in drug discovery, it is critical for drug companies to adapt their drafting strategies to the unique features of AI-generated inventions, and to pay particularly close attention to enablement standards, says Sanandan Malhotra at Novo Nordisk.

  • Series

    Law School's Missed Lessons: How To Start A Law Firm

    Author Photo

    Launching and sustaining a law firm requires skills most law schools don't teach, but every lawyer should understand a few core principles that can make the leap calculated rather than reckless, says Sam Katz at Athlaw.

  • Fed. Circ. Patent Decisions In 2025: An Empirical Review

    Author Photo

    In 2025, the Federal Circuit's increased output was not enough to keep up with its ever-growing patent case load, and patent owners and applicants fared poorly overall as the court's affirmance rate fell, says Dan Bagatell at Perkins Coie.

  • Regulatory Uncertainty Ahead For Organ Transplant System

    Author Photo

    Pending court cases against a Centers for Medicare and Medicaid Services final rule that introduced a competition-centric model for assessing organ procurement organizations' performance will significantly influence the path forward for such organizations and transplant hospitals, say attorneys at Crowell & Moring.

  • Key False Claims Act Trends From The Last Year

    Author Photo

    The False Claims Act remains a powerful enforcement tool after some record verdicts and settlements in 2025, and while traditional fraud areas remain a priority, new initiatives are raising questions about its expanding application, says Veronica Nannis at Joseph Greenwald.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.